University of Montana Research Could Provide Effective Treatment for Stroke and Traumatic Brain Injury – Sinapis Pharma

If Dave Poulsen’s research gets approval from federal regulators for medical use, Poulsen and his company Sinapis Pharma and his employer, the University of Montana, stand to make a lot of money on meth.

That’s right.

Poulsen’s unique methamphetamine application, which he co-developed with Nick Chandler, a former Missoula neurosurgeon, could generate millions in royalty payments for UM.

More important, this drug deal could save the lives of stroke victims – there are some 800,000 each year in this country alone – and dramatically improve the quality of life for those individuals, and also of people who suffer traumatic brain injuries.

Poulsen said he’s so confident about his research findings that “I know if I ever had a stroke or traumatic brain injury, I’d want to be treated with this stuff.”


All the promise and all the talent for turning academic exploration into profit are already in place at UM, said new Tech Transfer officer, Joe Fanguy , who at age 32 is a scientist-inventor, and most recently served as assistant director of Mississippi State University’s Office of Technology.

The challenge, however, is to inspire and create a culture at UM that embraces the notion.

By BETSY COHEN of the Missoulian

Full Story:


University of Montana Spinoff, Sinapis Pharma, Closes Series ‘A’ Financing

University of Montana Office of Technology Transfer

Montana State University Office of Technology Transfer:

Sorry, we couldn't find any posts. Please try a different search.

Leave a Comment

You must be logged in to post a comment.